185 related articles for article (PubMed ID: 28382147)
1. Gambogenic acid synergistically potentiates bortezomib-induced apoptosis in multiple myeloma.
Chen R; Zhang H; Liu P; Wu X; Chen B
J Cancer; 2017; 8(5):839-851. PubMed ID: 28382147
[No Abstract] [Full Text] [Related]
2. Inducing cell cycle arrest and apoptosis by dimercaptosuccinic acid modified Fe3O4 magnetic nanoparticles combined with nontoxic concentration of bortezomib and gambogic acid in RPMI-8226 cells.
Zhang W; Qiao L; Wang X; Senthilkumar R; Wang F; Chen B
Int J Nanomedicine; 2015; 10():3275-89. PubMed ID: 25995634
[TBL] [Abstract][Full Text] [Related]
3. Trifluoperazine Synergistically Potentiates Bortezomib-Induced Anti-Cancer Effect in Multiple Myeloma via Inhibiting P38 MAPK/NUPR1.
Jing Z; Yu W; Li A; Chen X; Chen Y; Chen J
Tohoku J Exp Med; 2022 Jul; 257(4):315-326. PubMed ID: 35644544
[TBL] [Abstract][Full Text] [Related]
4. Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo.
Jia C; Kong D; Guo Y; Li L; Quan L
Biochem Biophys Res Commun; 2018 Nov; 505(3):720-725. PubMed ID: 30292410
[TBL] [Abstract][Full Text] [Related]
5. Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.
Yang L; Zhang S; George SK; Teng R; You X; Xu M; Liu H; Sun X; Amin HM; Shi W
Oncotarget; 2015 Jun; 6(17):14953-69. PubMed ID: 25879451
[TBL] [Abstract][Full Text] [Related]
6. Gambogenic acid alters chemosensitivity of breast cancer cells to Adriamycin.
He Y; Ding J; Lin Y; Li J; Shi Y; Wang J; Zhu Y; Wang K; Hu X
BMC Complement Altern Med; 2015 Jun; 15():181. PubMed ID: 26066793
[TBL] [Abstract][Full Text] [Related]
7. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
[TBL] [Abstract][Full Text] [Related]
8. GRP78 inhibitor HA15 increases the effect of Bortezomib on eradicating multiple myeloma cells through triggering endoplasmic reticulum stress.
Chen Y; Tao Y; Hu K; Lu J
Heliyon; 2023 Sep; 9(9):e19806. PubMed ID: 37809599
[TBL] [Abstract][Full Text] [Related]
9. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
[TBL] [Abstract][Full Text] [Related]
10. [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms].
Mo HM; Wu QY; Han DY; Liu R; Ma X; Zhou P; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1053-1057. PubMed ID: 29365400
[No Abstract] [Full Text] [Related]
11. Targeting Glutaminolysis to Treat Multiple Myeloma: An
Li C; Feng Y; Wang W; Xu L; Zhang M; Yao Y; Wu X; Zhang Q; Huang W; Wang X; Li X; Ying P; Shang L
Anticancer Agents Med Chem; 2023; 23(7):779-785. PubMed ID: 36065917
[TBL] [Abstract][Full Text] [Related]
12. PEGylated liposomes as delivery systems for Gambogenic acid: Characterization and in vitro/in vivo evaluation.
Tang X; Sun J; Ge T; Zhang K; Gui Q; Zhang S; Chen W
Colloids Surf B Biointerfaces; 2018 Dec; 172():26-36. PubMed ID: 30125771
[TBL] [Abstract][Full Text] [Related]
13. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.
Du HF; Yu LJ; Meng YF; Lv HY; Meng J; Song XN; Zhang JQ
Leuk Lymphoma; 2013 Mar; 54(3):607-18. PubMed ID: 22889356
[TBL] [Abstract][Full Text] [Related]
14. [In vitro synergistic effect of bortezomib and pirarubicin on proliferation and apoptosis of T cell lymphoma cell line Hut-78 cells].
Qian ZZ; Wang HQ; Fu K; Ma YL; Hao XS
Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):47-51. PubMed ID: 21429402
[TBL] [Abstract][Full Text] [Related]
15. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
16. Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts.
Chen P; Yuan Q; Yang H; Wen X; You P; Hou D; Xie J; Cheng Y; Huang H
Leuk Res; 2017 Jun; 57():119-126. PubMed ID: 28463768
[TBL] [Abstract][Full Text] [Related]
17. [Cdc37 Contributes to bortezomib resistance in multiple myeloma via autophagy].
Liu LT; Deng SH; Zang MR; Zhang JQ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):583-588. PubMed ID: 32810966
[No Abstract] [Full Text] [Related]
18. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
[TBL] [Abstract][Full Text] [Related]
19. Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.
Zhang M; He J; Liu Z; Lu Y; Zheng Y; Li H; Xu J; Liu H; Qian J; Orlowski RZ; Kwak LW; Yi Q; Yang J
Oncotarget; 2015 Apr; 6(11):8567-78. PubMed ID: 25895124
[TBL] [Abstract][Full Text] [Related]
20. [Combined Effect of Bortezomib and Homoharringtonine on K562 Cells and their Mechanisms].
Xie C; Tang AP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):395-400. PubMed ID: 29665904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]